Rice Hall James & Associates LLC Acquires Shares of 490,221 Supernus Pharmaceuticals, Inc. $SUPN

Rice Hall James & Associates LLC acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 2nd quarter, Holdings Channel.com reports. The fund acquired 490,221 shares of the specialty pharmaceutical company’s stock, valued at approximately $22,800,000. Supernus Pharmaceuticals accounts for 1.1% of Rice Hall James & Associates LLC’s portfolio, making the stock its 28th largest holding.

A number of other hedge funds also recently modified their holdings of the stock. Royal Bank of Canada grew its stake in Supernus Pharmaceuticals by 68.1% in the 1st quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock valued at $382,000 after buying an additional 4,729 shares during the last quarter. AQR Capital Management LLC lifted its position in Supernus Pharmaceuticals by 35.2% during the first quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock worth $2,791,000 after acquiring an additional 22,182 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Supernus Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock worth $978,000 after acquiring an additional 1,297 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 370.5% during the first quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock worth $4,695,000 after acquiring an additional 112,886 shares during the period. Finally, Empowered Funds LLC boosted its holdings in shares of Supernus Pharmaceuticals by 16.0% during the first quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock worth $1,573,000 after acquiring an additional 6,619 shares during the period.

Supernus Pharmaceuticals Price Performance

SUPN stock opened at $48.27 on Tuesday. The company has a market cap of $2.81 billion, a PE ratio of -25.14, a price-to-earnings-growth ratio of 0.89 and a beta of 0.56. The business has a 50-day simple moving average of $46.54 and a 200 day simple moving average of $48.85. Supernus Pharmaceuticals, Inc. has a 52 week low of $41.78 and a 52 week high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($1.43). The firm had revenue of $219.06 million for the quarter, compared to the consensus estimate of $205.31 million. Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The company’s revenue for the quarter was up 32.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.40 EPS. On average, analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on SUPN shares. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Wall Street Zen downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Cantor Fitzgerald upped their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Finally, Zacks Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.83.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.